When.com Web Search

  1. Ad

    related to: reach 3 ruxolitinib 20 000 cap for sale

Search results

  1. Results From The WOW.Com Content Network
  2. Ruxolitinib - Wikipedia

    en.wikipedia.org/wiki/Ruxolitinib

    Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...

  3. Rociletinib - Wikipedia

    en.wikipedia.org/wiki/Rociletinib

    Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. [1]

  4. New Data for Jakafi® (ruxolitinib) Presented at the 2012 ...

    www.aol.com/news/2012-12-10-new-data-for-jakafi...

    New Data for Jakafi ® (ruxolitinib) Presented at the 2012 American Society of Hematology Annual Meeting In long-term results from two randomized Phase III clinical trials (COMFORT-I and COMFORT ...

  5. Cosibelimab - Wikipedia

    en.wikipedia.org/wiki/Cosibelimab

    Cosibelimab, sold under the brand name Unloxcyt, is a monoclonal antibody used for the treatment of cutaneous squamous-cell carcinoma. [1] It is a programmed death ligand-1 (PD-L1) blocking antibody.

  6. New Data for Jakafi® (ruxolitinib) to Be Presented at the ...

    www.aol.com/2012/12/07/new-data-for-jakafi...

    For premium support please call: 800-290-4726 more ways to reach us

  7. Navitoclax - Wikipedia

    en.wikipedia.org/wiki/Navitoclax

    At RP2D, 8/49 (16.3%) evaluable patients had a partial response (PR) with disease control rate (DCR) 59.2%. Though 35.2% objective response rate (0RR) and a disease control rate (DCR) of 85.7% was achieved among the 32 patients with GYN cancers, but the median duration of response (DOR) of 8.2 months was only moderately fine and no complete ...

  8. Two Indian companies indicted in US for importing ingredients ...

    www.aol.com/news/two-indian-companies-indicted...

    800-290-4726 more ways to reach us. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. ... Lathiya agreed to sell 20 kilograms of the precursor chemical ...

  9. Deuruxolitinib - Wikipedia

    en.wikipedia.org/wiki/Deuruxolitinib

    Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata. [1] It is a Janus kinase inhibitor selective for JAK1 and JAK2. [2]

  1. Ad

    related to: reach 3 ruxolitinib 20 000 cap for sale